{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:22:51Z","timestamp":1740144171833,"version":"3.37.3"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,12,21]],"date-time":"2015-12-21T00:00:00Z","timestamp":1450656000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research (GB)","doi-asserted-by":"publisher","award":["11\/119\/01"],"award-info":[{"award-number":["11\/119\/01"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1007\/s40273-015-0351-2","type":"journal-article","created":{"date-parts":[[2015,12,21]],"date-time":"2015-12-21T09:20:44Z","timestamp":1450689644000},"page":"463-477","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Rivaroxaban for Preventing Atherothrombotic Events in People with Acute Coronary Syndrome and Elevated Cardiac Biomarkers: An Evidence Review Group Perspective of a NICE Single Technology Appraisal"],"prefix":"10.1007","volume":"34","author":[{"given":"Abdullah","family":"Pandor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Pollard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Chico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matt","family":"Stevenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,12,21]]},"reference":[{"key":"351_CR1","volume-title":"Guide to the processes of technology appraisals","author":"National Institute for Health and Care Excellence (NICE)","year":"2014","unstructured":"National Institute for Health and Care Excellence (NICE). Guide to the processes of technology appraisals. London: NICE; 2014."},{"key":"351_CR2","volume-title":"Rivaroxaban for the prevention of adverse outcomes in patients after the acute management of acute coronary syndrome: a Single Technology Appraisal","author":"A Pandor","year":"2014","unstructured":"Pandor A, Pollard D, Stevenson M, Cantrell A, Chico T, Henderson R. Rivaroxaban for the prevention of adverse outcomes in patients after the acute management of acute coronary syndrome: a Single Technology Appraisal. Sheffield: School of Health and Related Research (ScHARR); 2014."},{"key":"351_CR3","unstructured":"National Institute for Health and Care Excellence (NICE). Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome. London: NICE; 2015. https:\/\/www.nice.org.uk\/guidance\/ta335\/documents . Accessed 10 Sept 2015."},{"key":"351_CR4","unstructured":"National Institute for Health and Care Excellence (NICE). Unstable angina and NSTEMI: the early management of unstable angina and non-ST segment elevation myocardial infarction (Clinical Guideline No. 94). London: NICE; 2010."},{"key":"351_CR5","volume-title":"Hospital episode statistics, admitted patient care, England 2012\u201313","author":"Health and Social Care Information Centre","year":"2013","unstructured":"Health and Social Care Information Centre. Hospital episode statistics, admitted patient care, England 2012\u201313. Leeds: Health and Social Care Information Centre; 2013."},{"key":"351_CR6","volume-title":"Patient episode database for wales statistics","author":"NHS Wales Informatics Service","year":"2013","unstructured":"NHS Wales Informatics Service. Patient episode database for wales statistics. Cardiff: NHS Wales Informatics Service; 2013."},{"key":"351_CR7","unstructured":"Gavalova L, Weston C. Myocardial Ischaemia National Audit Project. How the NHS cares for patients with heart attack. Annual Public Report April 2012\u2013March 2013. London: University College London; 2013."},{"issue":"4","key":"351_CR8","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1161\/CIRCOUTCOMES.111.964700","volume":"5","author":"K Smolina","year":"2012","unstructured":"Smolina K, Wright F, Rayner M, Goldacre M. Long-term survival and recurrence after acute myocardial infarction in England, 2004 to 2010. Circ Cardiovasc Qual Outcomes. 2012;5(4):532\u201340.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"351_CR9","unstructured":"National Institute for Health and Care Excellence (NICE). Ticagrelor for the treatment of acute coronary syndromes (Technology Appraisal No. 236). London: NICE; 2011."},{"key":"351_CR10","unstructured":"National Institute for Health and Care Excellence (NICE). Secondary prevention in primary and secondary care for patients following a myocardial infarction (Clinical Guideline No. 172). London: NICE; 2013."},{"key":"351_CR11","unstructured":"National Institute for Health and Care Excellence (NICE). Myocardial infarction with STEMI: the acute management of myocardial infarction with STEMI (Clinical Guideline No. 167). London: NICE; 2013."},{"key":"351_CR12","unstructured":"National Institute for Health and Care Excellence (NICE). Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes (review of technology appraisal guidance 182). (Technology Appraisal No. 317). London: NICE; 2014."},{"issue":"7578","key":"351_CR13","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1136\/bmj.38985.646481.55","volume":"333","author":"KAA Fox","year":"2006","unstructured":"Fox KAA, Dabbous OH, Goldberg RJ, Pieper KS, Eagle KA, Van de Werf F, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ. 2006;333(7578):1091\u20134.","journal-title":"BMJ"},{"issue":"4","key":"351_CR14","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3810\/pgm.2013.07.2682","volume":"125","author":"N Norgard","year":"2013","unstructured":"Norgard N, Dinicolantonio J. Clopidogrel, prasugrel, or ticagrelor? A practical guide to use of antiplatelet agents in patients with acute coronary syndromes. Postgrad Med. 2013;125(4):91\u2013102.","journal-title":"Postgrad Med"},{"issue":"23","key":"351_CR15","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehr236","volume":"32","author":"C Hamm","year":"2011","unstructured":"Hamm C, Bassand J, Agewall S, Bax J, Boersma E, Bueno H, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011;32(23):2999\u20133054.","journal-title":"Eur Heart J"},{"issue":"20","key":"351_CR16","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs215","volume":"33","author":"P Steg","year":"2012","unstructured":"Steg P, James S, Atar D, Badano L, Blomstrom-Lundqvist C, Borger M, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J. 2012;33(20):2569\u2013619.","journal-title":"Eur Heart J"},{"key":"351_CR17","volume-title":"Rivaroxaban (Xarelto)\u2014summary of product characteristics","author":"AG Bayer Pharma","year":"2013","unstructured":"Bayer Pharma AG. Rivaroxaban (Xarelto)\u2014summary of product characteristics. Berlin: Bayer Pharma AG; 2013."},{"key":"351_CR18","volume-title":"British national formulary","author":"Joint Formulary Committee","year":"2014","unstructured":"Joint Formulary Committee. British national formulary. London: BMJ Group and Pharmaceutical Press; 2014."},{"issue":"5","key":"351_CR19","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.ahj.2011.01.026","volume":"161","author":"CM Gibson","year":"2011","unstructured":"Gibson CM, Mega JL, Burton P, Goto S, Verheugt F, Bode C, et al. Rationale and design of the anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome. Am Heart J. 2011;161(5):815\u201321.","journal-title":"Am Heart J"},{"issue":"1","key":"351_CR20","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","volume":"366","author":"JL Mega","year":"2012","unstructured":"Mega JL, Braunwald E, Wiviott SD, Bassand J-P, Bhatt DL, Bode C, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366(1):9\u201319.","journal-title":"N Engl J Med"},{"issue":"33","key":"351_CR21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta5330","volume":"5","author":"S Brookes","year":"2001","unstructured":"Brookes S, Whitley E, Peters T, Mulheran P, Egger M, Davey Smith G. Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives. Health Technol Assess. 2001;5(33):1\u201356.","journal-title":"Health Technol Assess"},{"key":"351_CR22","doi-asserted-by":"crossref","first-page":"e1553","DOI":"10.1136\/bmj.e1553","volume":"344","author":"X Sun","year":"2012","unstructured":"Sun X, Briel M, Busse J, You J, Aki E, Mejza F, et al. Credibility of claims of subgroup effects in randomised controlled trials: systematic review. BMJ. 2012;344:e1553.","journal-title":"BMJ"},{"issue":"16","key":"351_CR23","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.jacc.2012.08.001","volume":"60","author":"K Thygesen","year":"2012","unstructured":"Thygesen K, Alpert J, Jaffe A, Simoons M, Chaitman B, White H. Joint ESC\/ACCF\/AHA\/WHF Task Force for Universal Definition of Myocardial Infarction Third universal definition of myocardial infarction. J Am Coll Cardiol. 2012;60(16):1581\u201398.","journal-title":"J Am Coll Cardiol"},{"key":"351_CR24","unstructured":"Food and Drug Administration (FDA). FDA Briefing Document for the Cardiovascular and Renal Drugs Advisory Committee Meeting January 16, 2014. Available at: http:\/\/www.fda.gov\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/CardiovascularandRenalDrugsAdvisoryCommittee\/ucm378911.htm . Accessed 3 Oct 2015."},{"key":"351_CR25","unstructured":"European Medicines Agency (EMA). Assessment Report for Xarelto. Procedure Number: EMEA\/H\/C\/000944\/X\/00017. London: EMA; 2014."},{"key":"351_CR26","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1136\/bmj.332.7547.969","volume":"332","author":"J Dumville","year":"2006","unstructured":"Dumville J, Torgerson D, Hewitt E. Reporting attrition in randomised controlled trials. BMJ. 2006;332:969\u201371.","journal-title":"BMJ"},{"issue":"8","key":"351_CR27","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","volume":"365","author":"JH Alexander","year":"2011","unstructured":"Alexander JH, Lopes RD, James S, Kilaru R, He YH, Mohan P, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011;365(8):699\u2013708.","journal-title":"N Engl J Med"},{"issue":"1","key":"351_CR28","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1109719","volume":"366","author":"P Tricoci","year":"2012","unstructured":"Tricoci P, Huang Z, Held C, Moliterno DJ, Armstrong PW, Van de Werf F, et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med. 2012;366(1):20\u201333.","journal-title":"N Engl J Med"},{"key":"351_CR29","unstructured":"US Food and Drug Administration. Ticagrelor NDA 22\u2013433 Briefing Document for Cardiovascular and Renal Drugs Advisory Committee Meeting. Available at: http:\/\/www.fda.gov\/downloads\/AdvisoryCommitteesMeetingMaterials\/Drugs\/CardiovascularandRenalDrugsAdvisoryCommittee\/UCM220197.pdf . Accessed 5 Oct 2015."},{"key":"351_CR30","unstructured":"US Food and Drug Administration. February 3, 2009, Meeting of the Cardiovascular and Renal Drugs. Briefing Information for the February 3, 2009 Meeting of the Cardiovascular and Renal Drugs Advisory Committee. FDA briefing material. Available at: http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/CardiovascularandRenalDrugsAdvisoryCommittee\/UCM181185.pdf . Accessed 5 Oct 2015."},{"issue":"9","key":"351_CR31","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jacc.2013.05.024","volume":"62","author":"MJ Krantz","year":"2013","unstructured":"Krantz MJ, Kaul S. The ATLAS ACS 2-TIMI 51 trial and the burden of missing data (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome ACS 2-Thrombolysis In Myocardial Infarction 51). J Am Coll Cardiol. 2013;62(9):777\u201381.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"351_CR32","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1161\/CIRCULATIONAHA.106.612812","volume":"114","author":"JW Eikelboom","year":"2006","unstructured":"Eikelboom JW, Mehta SR, Anand SS, Xie CC, Fox KAA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006;114(8):774\u201382.","journal-title":"Circulation"},{"issue":"11","key":"351_CR33","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1161\/CIRCULATIONAHA.111.060871","volume":"125","author":"G Ndrepepa","year":"2012","unstructured":"Ndrepepa G, Schuster T, Hadamitzky M, Byrne RA, Mehilli J, Neumann FJ, et al. Validation of the Bleeding Academic Research Consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention. Circulation. 2012;125(11):1424\u201331.","journal-title":"Circulation"},{"issue":"24","key":"351_CR34","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1161\/CIRCULATIONAHA.107.694273","volume":"116","author":"FA Spencer","year":"2007","unstructured":"Spencer FA, Moscucci M, Granger CB, Gore JM, Goldberg RJ, Steg PG, et al. Does comorbidity account for the excess mortality in patients with major bleeding in acute myocardial infarction? Circulation. 2007;116(24):2793\u2013801.","journal-title":"Circulation"},{"key":"351_CR35","unstructured":"Department of Health (DoH). NHS reference costs 2012\u20132013. London: DoH; 2013. Availiable at: https:\/\/www.gov.uk\/government\/publications\/nhs-reference-costs-2012-to-2013 ."},{"issue":"12","key":"351_CR36","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.2165\/00019053-200725120-00007","volume":"25","author":"B Heeg","year":"2007","unstructured":"Heeg B, Damen J, Van Hout B. Oral antiplatelet therapy in secondary prevention of cardiovascular events\u2014an assessment from the payer\u2019s perspective. Pharmacoeconomics. 2007;25(12):1063\u201382.","journal-title":"Pharmacoeconomics"},{"key":"351_CR37","volume-title":"Ticagrelor for the treatment of acute coronary syndromes: a Single Technology Appraisal","author":"J Greenhalgh","year":"2011","unstructured":"Greenhalgh J, Bagust A, Boland A, Blundell M, Lai M, Dundar Y, et al. Ticagrelor for the treatment of acute coronary syndromes: a Single Technology Appraisal. LRiG: University of Liverpool; 2011."},{"issue":"5","key":"351_CR38","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1524-4733.2010.00700.x","volume":"13","author":"R Ara","year":"2010","unstructured":"Ara R, Brazier JE. Populating an economic model with health state utility values: moving toward better practice. Value Health. 2010;13(5):509\u201318.","journal-title":"Value Health"},{"key":"351_CR39","unstructured":"National Institute for Health and Care Excellence (NICE). Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome. NICE technology appraisal guidance 335. Available at: https:\/\/www.nice.org.uk\/guidance\/ta335\/resources\/guidance-rivaroxaban-for-preventing-adverse-outcomes-after-acute-management-of-acute-coronary-syndrome-pdf . Accessed 5 Oct 2015."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-015-0351-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-015-0351-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-015-0351-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T15:45:01Z","timestamp":1559490301000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-015-0351-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,21]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["351"],"URL":"https:\/\/doi.org\/10.1007\/s40273-015-0351-2","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"type":"print","value":"1170-7690"},{"type":"electronic","value":"1179-2027"}],"subject":[],"published":{"date-parts":[[2015,12,21]]}}}